伊立替康联合替吉奥治疗晚期结肠癌的疗效分析及对血清VEGF、MMP-9的影响

Effect of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Potassium Capsules in the Treatment of Late Colonic Cancer,and the Influence on Serum VEGF and MMP-9

为探讨伊立替康联合替吉奥治疗晚期结肠癌的临床疗效及对血清VEGF、MMP-9的影响,将90例晚期结肠癌患者随机分为对照组和观察组,每组45例。对照组患者采用FOLFIRI方案治疗,观察组患者采用伊立替康联合替吉奥治疗,比较2组患者临床疗效及治疗前后血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平。结果显示,观察组患者治疗总有效率明显高于对照组,P<0.05;治疗后观察组患者血清VEGF、MMP-9水平均低于对照组,P<0.05。2组患者恶心呕吐、中性粒细胞减少、腹泻、肝功能异常发生率比较差异均无统计学意义,P>0.05。结果表明,伊立替康联合替吉奥治疗晚期结肠癌疗效显著,可明显降低患者血清VEGF、MMP-9水平,有积极推广意义。

This study was to investigate the effect of Irinotecan combined with Tegafur,Gimeracil and Oteracil potassium capsules(TGO)in the treatment of late colonic cancer,and the influence on serum VEGF and MMP-9,randomly divided 90 patients with late colonic cancer into control group(45 cases,FOLFIRI scheme for treating)and observation group(45 cases,TGO plus Irinotecan);then,compared both groups’clinical effect,and levels of VEGF and MMP-9.As results,after treatment in total effective rate and in the serum levels of VEGF and MMP-9 observation group was respectively higher,and lower than control group(all,P<0.05);in the incidences of nausea&vomiting,neutropenia,diarrhea,and dyshepatia there was no statistical difference between the two groups(P>0.05).Results show that irinotecan plus TGO in the treatment of late colonic cancer has significant effect,can distinctly decrease the levels of VEGF and MMP-9,thus has popularized significance.